Drug intelligence / Profile preview

Tongmai Yangxin Pills

Development stage: Phase 4
Administration: Oral

Overview

Tongmai Yangxin Pills (TMYX) is a traditional Chinese patent medicine composed of 11 herbs, originating from two classic prescriptions: Zhigancao Decoction and Shenmai Yin. It is primarily used for treating various cardiovascular conditions including coronary heart disease, chest pain, palpitations, angina, and irregular heartbeat. The medication works through multiple mechanisms including anti-inflammatory effects (regulating ESR1 and NF-κB signaling), cardiac pacemaking modulation (affecting HCN channels and cAMP), myocardial no-reflow improvement (activating PI3K/Akt/eNOS pathway), and intervention in ventricular remodeling.

Brand names: Tongmai Yangxin Pills
Other names: Tongmai Yangxin Pill

Targets

AKT (RAC-alpha serine/threonine-protein kinase)NOS3 (eNOS)ESR1 (ERα)HCN (HCN channel family)NF-κBPI3K (Phosphoinositide-3-kinase regulatory subunit 6)

Beyond the preview

Go deeper on Tongmai Yangxin Pills.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tongmai Yangxin Pills.